Celgene Corporation

Canna Chemistries LLC

Astrazeneca Ab

Nektar Therapeutics

Acadia Pharmaceuticals Inc.

Astrocyte Pharmaceuticals, Inc.

Idenix Pharmaceuticals, Inc.

Novartis Pharma Ag

Takeda Pharmaceuticals U.s.a., Inc.

Aurigene Oncology Limited

Askat Inc.

Mutual Pharamaceutical Company, Inc.

David Thomas Jonaitis

Ho-Wah Hui

G Patrick Stahly

Kevin Joseph Klopfer

Stephan D Parent

Lisa M McCracken

Martin Hans Bohlin

Marlon Carlos

Carl-Johan Aurell

Richard Storer

Tong Sun

Tesfai Sebhatu

Cecilia Betti

Martin Bernard Catherine Bousmanne

Nate Schultheiss

Matthew Peterson

Lisa M Grove

Nico Setiawan

Lloyd Steven Miller

Nathan Schultheiss

Emily Rigsbee

David Richard Jensen

Eric Thomas Healy

Lisa Michelle Grove

Russell Birch Poe

Alfredo C Castro

Stephen David Cosgrove

Bo Ingvar Ymén

Bengt Leonard Åslund

Jonathan Charles Derrick Sutch

Bo Ingvar Ymen

Bengt Aslund

Oskari Karjalainen

Stephan Parent

Bengt Leonard Aslund

Bo Ingvar YMÉN

Bengt Leonard ÅSlund

This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.

Crystalline forms of trofinetide

Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.

Crystalline salts of psilocin

The present invention provides co-crystal and salt forms, and compositions and methods thereof, useful for treating various diseases, disorders or conditions in which EP4 prostaglandin receptors are implicated in the mediation of a proliferative disorder, by the administration of small molecule therapeutics acting as inhibitors of prostaglandin EP4 receptor activity.

Polymorphic compounds and uses thereof

The invention relates to a solid Δ-THC composition containing Δ-THC and a powder former and having a molar ratio of Δ-THC to powder former to form a flowable Δ-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, β-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid Δ-THC composition of the invention. The Δ-THC may be synthetic Δ-THC or may be extracted Δ-THC. The invention provides pharmaceutical or nutraceutical composition containing a solid Δ-THC composition of the invention and a pharmaceutically- or nutraceutically-acceptable carrier where Δ-THC is present in a pharmaceutically or nutraceutically effective amount. The invention also provides methods of treating a disease, disorder, or condition by administering to a patient in need thereof a therapeutically effective amount of a solid Δ-THC composition. A solid Δ-THC composition of the invention may also be incorporated into food and beverage products.

Solid Δ-tetrahydrocannabinol (Δ-THC) compositions

The present invention relates to novel hydrochloride salt forms of N-(2′,4′-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1′-biphenyl]-3-yl)cyclopropanesulfonamide (I). Compound (I) is a selective inhibitor of FGFR/VEGFR kinase families and is useful in the treatment of cancer.

Hydrochloride salt forms of a sulfonamide structured kinase inhibitor

The invention relates to a solid &#x394;-THC composition containing &#x394;-THC and a powder former and having a molar ratio of &#x394;-THC to powder former to form a flowable &#x394;-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, &#x3b2;-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid &#x394;-THC composition of the invention. The &#x394;-THC may be synthetic &#x394;-THC or may be extracted &#x394;-THC. The invention provides pharmaceutical or nutraceutical composition containing a solid &#x394;-THC composition of the invention and a pharmaceutically- or nutraceutically-acceptable carrier where &#x394;-THC is present in a pharmaceutically or nutraceutically effective amount. The invention also provides methods of treating a disease, disorder, or condition by administering to a patient in need thereof a therapeutically effective amount of a solid &#x394;-THC composition. A solid &#x394;-THC composition of the invention may also be incorporated into food and beverage products.

Solid &#x394;-tetrahydrocannabinol (&#x394;-THC) compositions

Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.

Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof

The present invention provides compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

Solid forms comprising 4-amino-2-(2,6- dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof

Provided herein are solid forms comprising (a) 4-amino-1-&#x3b2;-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.

Solid forms comprising 4-amino-1-&#x3b2;-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof

Growing community of inventors

West Lafayette, IN, United States of America

David Thomas Jonaitis